Opinion

Video

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
1 KOL is featured in this series.
Related Content
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 10th 2024

Talazoparib/enzalutamide significantly boosts OS in mCRPC

Benjamin P. Saylor Jason M. Broderick Conor Killmurray
"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA approves study of Aquablation vs radical prostatectomy in prostate cancer
October 8th 2024

FDA approves study of Aquablation vs radical prostatectomy in prostate cancer

Hannah Clarke
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care
October 1st 2024

Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care

Kevin Kunzmann
Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.
Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer
September 30th 2024

Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer

Kevin Kunzmann
Findings from GETUG 14 show short-term ADT with high-dose radiotherapy provided 5-year improved efficacy without increased risk of toxicity.
© 2024 MJH Life Sciences

All rights reserved.